6.3.4.5: argininosuccinate synthase
This is an abbreviated version!
For detailed information about argininosuccinate synthase, go to the full flat file.
Word Map on EC 6.3.4.5
-
6.3.4.5
-
ornithine
-
citrullinemia
-
arginase
-
ammonia
-
hyperammonemia
-
deiminase
-
transcarbamylase
-
l-arginine
-
pegylated
-
auxotrophic
-
adi-peg20
-
carbamyl
-
adult-onset
-
coma
-
argininosuccinase
-
carbamoylphosphate
-
carbamoyltransferase
-
citrin
-
tropoelastin
-
urea-cycle
-
consciousness
-
medicine
-
ureogenesis
-
elastogenesis
-
ornithine-urea
-
elastin-derived
-
jararaca
-
coinduction
-
bothrops
-
n-acetylglutamate
-
drug development
-
molecular biology
- 6.3.4.5
- ornithine
- citrullinemia
- arginase
- ammonia
- hyperammonemia
- deiminase
-
transcarbamylase
- l-arginine
-
pegylated
-
auxotrophic
-
adi-peg20
-
carbamyl
-
adult-onset
- coma
- argininosuccinase
- carbamoylphosphate
-
carbamoyltransferase
-
citrin
- tropoelastin
-
urea-cycle
-
consciousness
- medicine
-
ureogenesis
-
elastogenesis
-
ornithine-urea
-
elastin-derived
- jararaca
-
coinduction
-
bothrops
- n-acetylglutamate
- drug development
- molecular biology
Reaction
Synonyms
ARGG, Arginine succinate synthetase, argininosuccinate synthase, argininosuccinate synthase 1, Argininosuccinate synthetase, Argininosuccinic acid synthetase, arininosuccinate synthetase, AS, ASS, ASS1, Citrulline--aspartate ligase, Citrulline-aspartate ligase, EAS, Elastin-binding protein, PyARG1, Synthetase, argininosuccinate, tAsS
ECTree
6.3.4.5 argininosuccinate synthaseAdvanced search results
results (
results (Application
Application on EC 6.3.4.5 - argininosuccinate synthase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
drug development
-
high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis
medicine
molecular biology
report in which the function of a Porphyra yezoensis gene has been directly demonstrated by the rescue of a Saccharomyces cerevisiae mutant. This technique may provide new opportunities for further investigations into the functions of various genes in Porphyra yezoensis and other macroalgal species
medicine
-
AS and GTP cyclohydrolase I are intimately associated with inflammatory arthritis, they may be important modulators of arthritis and may represent novel targets for modulation of disease activity
medicine
-
citrulline-arginine recycling enzyme, intervention in the supply of arginine may represent a new therapeutic approach to the treatment of NO-mediated neurodegenerative damage in the brain
medicine
-
neuronal and glial ASS expression is increased in brains of patients with Alzheimer disease
medicine
-
a case of late-onset CTLN1 (citrullinemia) in a patient is described by biochemical analyses and ASS gene mutation confirmation. This is the first report of a Korean patient with late-onset CTLN1 confirmed by ASS gene mutation identification
medicine
-
argininosuccinate synthetase is inhibited by endotoxin, implying that bacterial products might potentially regulate the arginine metabolism in the host and perturb NO synthesis
medicine
-
the downregulation of tumor necrosis factor-alpha is an added insult to endothelial function because of its important role in NO production and in endothelial viability
medicine
-
transient ischemia induces changes in nitric oxide synthase, argininosuccinate synthetase and argininsuccinate lyase co-expression in the rat striatal neurons. At 24 h after reperfusion in the animals with a longer survival and better motor-sensory performances there is an increase in these neuronal populations. It is hypothesized that the elevated expression of argininosuccinate synthetase and argininsuccinate lyase protects ischemic striatal neurons from tissue damages by maintaining a correct NO production
medicine
argininosuccinate synthase 1 is upregulated in primary human colorectal tumors and pharmacological inhibition or genetic ablation of ASS1 impairs colorectal cancer pathogenicity. ASS1 inhibition leads to reductions in the levels of oncogenic metabolite fumarate, leading to impairments in glycolytic metabolism that supports colorectal cancer cell pathogenicity
medicine
argininosuccinate synthase Ass contributes to ethanol plus Fas/CD95 agonistic antibody Jo2-mediated liver injury. NOS2 induction, 3-nitrotyrosine adducts formation and elevated nitrites, nitrates and S-nitrosothiols are higher in livers from wild-type mice than from Ass+/- mice
medicine
argininosuccinate synthase ASS1 is significantly downregulated in the urine of 30 depressed subjects while remaining unchanged in the plasma. ASS1 displays strong efficacy in distinguishing major depressive disorder subjects from healthy controls
medicine
unclassified hepatocellular carcinomas display specific up-regulation of the arginine synthesis pathway associated with overexpression of argininosuccinate synthase (ASS1) and arginosuccinate lyase. All the unclassified hepatocellular carcinomas tested could be identified by ASS1 immunohistochemistry, and 64.7% of these carcinomas presented clinical bleeding manifestations. The significance of ASS1 also encompasses certain hemorrhagic cases, particularly inflammatory hepatocellular carcinomas
